Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

Blood tests of liver injury are less well validated in non‐alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis.

Chris Day | Fritz Wrba | Debbie Lawlor | Alastair D. Burt | Philippe Giral | Peter Schirmacher | Dominique Thabut | Pierre Bedossa | Giulio Marchesini | D. Lawlor | M. Ziol | P. Schirmacher | G. Marchesini | Y. Ngo | M. Rudler | D. Thabut | J. Dufour | L. Terracciano | P. Bedossa | M. Trauner | A. Gouw | P. Giral | A. Hartemann | E. Bruckert | F. Wrba | F. Marra | S. Bellentani | E. Bugianesi | M. Montani | D. Wendum | A. Burt | H. Perazzo | S. Jacqueminet | C. Lackner | Y. Calmus | G. Perlemuter | Q. Anstee | T. Poynard | V. Ratziu | L. Losi | O. Deckmyn | M. Munteanu | J. Moussalli | P. Lebray | F. Charlotte | O. Rosmorduc | D. Cabibi | C. Day | Michael Trauner | Eric Bruckert | S. Naveau | A. Mercadier | Thierry Poynard | Vlad Ratziu | Stefano Bellentani | S. de Minicis | D. Tiniakos | Sylvie Naveau | Carolin Lackner | Elisabetta Bugianesi | Frederic Charlotte | E. David | Matteo Montani | Olivier Rosmorduc | Luisa Losi | H. Perazzo | J. Brain | Luigi Terracciano | Daniela Cabibi | Joseph Moussalli | Pascal Lebray | Marika Rudler | Yen Ngo | Fabio Marra | Anne Mercadier | Marianne Ziol | P. Bedossa | Gabriel Perlemuter | M. Munteanu | D. Tiniakos | Q. Anstee | F. Charlotte | G. Marchesini | E. Bugianesi | M. Trauner | M. Romero Gomez | C. Oliveira | C. Day | J.‐F. Dufour | S. Bellentani | Y. Ngo | S. Traussnig | O. Deckmyn | V. Ratziu | T. Poynard | Jean‐Marie Castille | Tania Langon | Dina Tiniakos | Jean‐François Dufour | Manuel Romero Gomez | Thorkild Sørensen | Claudio Tribelli | Samuele De Minicis | Claudia Oliveira | Annette S.H. Gouw | J. Brain | Yvonne Bury | Ezio David | Marıa Jesus Pareja | Dominique Wendum | Françoise Imbert Bismuth | Yvon Calmus | Agnes Hartemann | Sophie Jacqueminet | Brigitte Varsat | M. Romero Gómez | J. Castille | Y. Bury | M. Pareja | F. Bismuth | C. Oliveira | B. Varsat | T. Langon | C. Oliveira | S. Traussnig | T. Sørensen | Claudio Tribelli

[1]  F. Pattou,et al.  Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity , 2011, European journal of gastroenterology & hepatology.

[2]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[3]  L. Castéra,et al.  Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation , 2007, Alimentary pharmacology & therapeutics.

[4]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[5]  Y. Ngo,et al.  Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. , 2012, Journal of hepatology.

[6]  V. de Lédinghen,et al.  An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. , 2015, Journal of hepatology.

[7]  P. Giral,et al.  Screening for liver disease using non‐invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia , 2006, Alimentary pharmacology & therapeutics.

[8]  Dominique Thabut,et al.  The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis , 2005, Comparative hepatology.

[9]  Julien Vergniol,et al.  Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[10]  S. Friedman,et al.  Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. , 2016, Contemporary clinical trials.

[11]  V. de Lédinghen,et al.  Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). , 2014, Journal of hepatology.

[12]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[13]  Y. Ngo,et al.  Open Access Research Article Prevalence of Liver Fibrosis and Risk Factors in a General Population Using Non-invasive Biomarkers (fibrotest) , 2022 .

[14]  Tao Jiang,et al.  Assessment of liver fibrosis: The relationship between point shear wave elastography and quantitative histological analysis , 2015, Journal of gastroenterology and hepatology.

[15]  V. de Lédinghen,et al.  Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®). , 2014, Journal of hepatology.

[16]  Roger Chou,et al.  Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection , 2013, Annals of Internal Medicine.

[17]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[18]  Y. Ngo,et al.  Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease , 2009, Hepatology.

[19]  V. de Lédinghen,et al.  FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. , 2011, Clinics and research in hepatology and gastroenterology.

[20]  M. Bulsara,et al.  Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease , 2011, Journal of gastroenterology and hepatology.

[21]  M. Manns,et al.  A comparison of fibrosis progression in chronic liver diseases. , 2003, Journal of hepatology.

[22]  K. Bandeen-Roche,et al.  Appendix 1 , 2019, European Journal of Human Genetics.

[23]  M. Friedrich-Rust,et al.  Critical comparison of elastography methods to assess chronic liver disease , 2016, Nature Reviews Gastroenterology &Hepatology.

[24]  D. Thabut,et al.  Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors , 2004, Clinical chemistry and laboratory medicine.

[25]  F. Carrat,et al.  How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. , 2008, Clinical chemistry.

[26]  V. de Lédinghen,et al.  Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. , 2007, Clinical chemistry.

[27]  Y. Ngo,et al.  Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity , 2015, BMJ Open.

[28]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[29]  Dominique Thabut,et al.  Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease , 2006, BMC gastroenterology.

[30]  V. de Lédinghen,et al.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.

[31]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[32]  Raimund Erbel,et al.  Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort , 2015, Scientific Reports.

[33]  K. Clément,et al.  Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data , 2012, PloS one.

[34]  L. Nguyen,et al.  Systematic review with meta‐analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis , 2014, Alimentary pharmacology & therapeutics.

[35]  V. de Lédinghen,et al.  ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. , 2010, Gastroenterologie clinique et biologique.

[36]  A. Mangia,et al.  The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases , 2011, Alimentary pharmacology & therapeutics.

[37]  D. Thabut,et al.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C , 2004, Comparative hepatology.

[38]  Ron-Li Liaw,et al.  Department of , 1993 .

[39]  R H Ebert,et al.  The medical school. , 1973, Scientific American.

[40]  Y. Ngo,et al.  Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B , 2015, Alimentary pharmacology & therapeutics.

[41]  Paul Nguyen.  nonbinROC: Software for Evaluating Diagnostic Accuracies with Non-Binary Gold Standards , 2007 .

[42]  Y. Ngo,et al.  Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[43]  Y. Ngo,et al.  Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia , 2014, Alimentary pharmacology & therapeutics.

[44]  V. de Lédinghen,et al.  Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease , 2006, BMC gastroenterology.

[45]  Patrice Cacoub,et al.  Meta-analyses of FibroTest diagnostic value in chronic liver disease , 2007, BMC gastroenterology.

[46]  Paul Calès,et al.  Sources of variability in histological scoring of chronic viral hepatitis , 2005, Hepatology.

[47]  Y. Ngo,et al.  Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age , 2011, BMC gastroenterology.

[48]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[49]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.